Literature DB >> 8137682

Smoking is associated with progression of diabetic nephropathy.

P T Sawicki1, U Didjurgeit, I Mühlhauser, R Bender, L Heinemann, M Berger.   

Abstract

OBJECTIVE: To investigate the association between cigarette smoking and the progression of diabetic nephropathy. RESEARCH DESIGN AND METHODS: A prospective, follow-up study over one year was conducted in a sequential sample of 34 smokers, 35 nonsmokers, and 24 ex-smokers with type I diabetes, hypertension, and diabetic nephropathy. Progression of renal disease was defined according to the stage of nephropathy as an increase in proteinuria or serum creatinine or a decrease in the glomerular filtration rate.
RESULTS: Progression of nephropathy was less common in nonsmokers (11%) than in smokers (53%) and patients who had quit smoking (33%), P < 0.001. In a stepwise logistic regression analysis, cigarette pack years, 24-h sodium excretion, and GHb were independent predictive factors for the progression of diabetic nephropathy. Because blood pressure (BP) was well controlled in these patients and most values were within a normotensive range, neither standing, sitting, nor supine BP values were associated with progression of nephropathy.
CONCLUSIONS: Cigarette smoking represents an important factor associated with progression of nephropathy in treated hypertensive type I diabetic patients.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8137682     DOI: 10.2337/diacare.17.2.126

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  39 in total

1.  Smoking and arterial stiffness in youth with type 1 diabetes: the SEARCH Cardiovascular Disease Study.

Authors:  Amy S Shah; Dana Dabelea; Jennifer W Talton; Elaine M Urbina; Ralph B D Agostino; R Paul Wadwa; Santica Marcovina; Richard F Hamman; Stephen R Daniels; Lawrence M Dolan
Journal:  J Pediatr       Date:  2014-03-27       Impact factor: 4.406

2.  Nicotine, smoking, podocytes, and diabetic nephropathy.

Authors:  Edgar A Jaimes; Ming-Sheng Zhou; Mohammed Siddiqui; Gabriel Rezonzew; Runxia Tian; Surya V Seshan; Alecia N Muwonge; Nicholas J Wong; Evren U Azeloglu; Alessia Fornoni; Sandra Merscher; Leopoldo Raij
Journal:  Am J Physiol Renal Physiol       Date:  2021-01-18

Review 3.  Primary and Secondary Prevention of Cardiovascular Disease in Patients with Chronic Kidney Disease.

Authors:  Sehrish Ali; Natasha Dave; Salim S Virani; Sankar D Navaneethan
Journal:  Curr Atheroscler Rep       Date:  2019-06-22       Impact factor: 5.113

4.  Evidence-based practice guideline for the treatment of CKD.

Authors: 
Journal:  Clin Exp Nephrol       Date:  2009-12       Impact factor: 2.801

5.  Prediction, progression and prevention of diabetic nephropathy. The Minkowski Lecture 2005.

Authors:  P Rossing
Journal:  Diabetologia       Date:  2005-12-09       Impact factor: 10.122

6.  A six-year follow-up study of smoking habits and microvascular complications in young adults with type 1 diabetes.

Authors:  R N Sinha; A W Patrick; L Richardson; M Wallymahmed; I A MacFarlane
Journal:  Postgrad Med J       Date:  1997-05       Impact factor: 2.401

Review 7.  [Protection of renal function in diabetics].

Authors:  C Hasslacher
Journal:  Internist (Berl)       Date:  2007-07       Impact factor: 0.743

8.  Machine Learning Approaches for Detecting Diabetic Retinopathy from Clinical and Public Health Records.

Authors:  Omolola Ogunyemi; Dulcie Kermah
Journal:  AMIA Annu Symp Proc       Date:  2015-11-05

9.  Cost effectiveness of ACE inhibitor treatment for patients with type 1 diabetes mellitus.

Authors:  Frederick B Dong; Stephen W Sorensen; Diane L Manninen; Theodore J Thompson; Venkat Narayan; Carlyn E Orians; Edward W Gregg; Richard C Eastman; Erik J Dasbach; William H Herman; Jeffrey M Newman; Andrew S Narva; David J Ballard; Michael M Engelgau
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

10.  Diabetic nephropathy.

Authors:  Themis Zelmanovitz; Fernando Gerchman; Amely Ps Balthazar; Fúlvio Cs Thomazelli; Jorge D Matos; Luís H Canani
Journal:  Diabetol Metab Syndr       Date:  2009-09-21       Impact factor: 3.320

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.